ACB begins probe into Delhi medicine shortage scam

Published On 2017-06-02 10:58 GMT   |   Update On 2017-06-02 10:58 GMT
Advertisement

NEW DELHI: The Anti-Corruption Branch has begun a probe into allegations by sacked Delhi minister Kapil Mishra about a scam in the procurement of medicines for government hospitals.


A probe has been ordered and searches are being carried out at various places, ACB sources said. The anti-graft body is likely to write to the Delhi government to share details about the procurement of medicines.


Mishra had claimed that the powers of Delhi government-run hospitals to buy medicines were put to an end by Delhi Chief Minister Arvind Kejriwal at the behest of Health Minister Satyendar Jain.


"Jain has himself admitted that Rs 300 crore have been allocated to procure medicines. The Delhi government boasts of having the highest budget earmarked for the health sector. In such a scenario how come there is a shortage of medicines. This is a scam," Mishra had alleged.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News